166 related articles for article (PubMed ID: 32445277)
1. Exhalation delivery system with fluticasone improves quality of life and health status: pooled analysis of phase 3 trials NAVIGATE I and II.
Soler ZM; Colman S; Velez FF; Schlosser RJ
Int Forum Allergy Rhinol; 2020 Jul; 10(7):848-855. PubMed ID: 32445277
[TBL] [Abstract][Full Text] [Related]
2. NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal Polyps.
Sindwani R; Han JK; Soteres DF; Messina JC; Carothers JL; Mahmoud RA; Djupesland PG
Am J Rhinol Allergy; 2019 Jan; 33(1):69-82. PubMed ID: 30477309
[TBL] [Abstract][Full Text] [Related]
3. NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis.
Leopold DA; Elkayam D; Messina JC; Kosik-Gonzalez C; Djupesland PG; Mahmoud RA
J Allergy Clin Immunol; 2019 Jan; 143(1):126-134.e5. PubMed ID: 29928924
[TBL] [Abstract][Full Text] [Related]
4. Effects of Fluticasone Exhalation Delivery System in Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review.
Wu D; Huang T; Wei Y
Am J Rhinol Allergy; 2022 Mar; 36(2):176-184. PubMed ID: 34342516
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the exhalation delivery system with fluticasone in patients with chronic rhinosinusitis with nasal polyps whose symptoms recur after sinus surgery.
Ow RA; Soler ZM; Sindwani R; Leopold DA; Lee JT; Mahmoud RA; Han JK
Int Forum Allergy Rhinol; 2023 Jan; 13(1):31-41. PubMed ID: 35674488
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the exhalation delivery system with fluticasone in patients who remain symptomatic on standard nasal steroid sprays.
Senior BA; Schlosser RJ; Bosso J; Soler ZM
Int Forum Allergy Rhinol; 2021 May; 11(5):837-845. PubMed ID: 32970395
[TBL] [Abstract][Full Text] [Related]
7. The Effect of EDS-FLU on Objective and Patient-Reported Subjective Outcomes for Patients with Chronic Rhinosinusitis with Nasal Polyps.
Ow RA; McGinnis JP; Sacks HJ; Mehle ME
Ear Nose Throat J; 2022 Apr; ():1455613221088698. PubMed ID: 35437059
[TBL] [Abstract][Full Text] [Related]
8. EXHANCE-3: a cohort study of the exhalation delivery system with fluticasone for chronic sinusitis with or without nasal polyps.
Sher MR; Steven GC; Romett JL; Pien G; LeBenger K; Messina JC; Carothers JL; Mahmoud RA; Djupesland PG
Rhinology; 2020 Feb; 58(1):25-35. PubMed ID: 31815255
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of EDS-FLU for Chronic Rhinosinusitis: Two Randomized Controlled Trials (ReOpen1 and ReOpen2).
Palmer JN; Adappa ND; Chandra RK; Davis GE; Mahdavinia M; Messina J; Ow RA; Patel ZM; Peters AT; Sacks H; Schlosser RJ; Sindwani R; Soler ZM; White AA; Wise SK; Mahmoud RA
J Allergy Clin Immunol Pract; 2024 Apr; 12(4):1049-1061. PubMed ID: 38244014
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the ocular safety associated with the exhalation delivery system with fluticasone.
Skoner DP; Meltzer EO; Skoner J; Sacks HJ; Lumry WR
Allergy Asthma Proc; 2022 Jan; 43(1):70-77. PubMed ID: 34753535
[No Abstract] [Full Text] [Related]
11. Exhalation Delivery Systems for Application of Intranasal Corticosteroids.
Kovacs AJ; Adappa ND; Kuan EC
Ear Nose Throat J; 2021 Jun; 100(5):309-313. PubMed ID: 33305974
[TBL] [Abstract][Full Text] [Related]
12. What is the evidence for fluticasone exhalation delivery system in chronic rhinosinusitis?
Kovacs AJ; Goshtasbi K; Kuan EC
Curr Opin Otolaryngol Head Neck Surg; 2020 Feb; 28(1):14-17. PubMed ID: 31789927
[TBL] [Abstract][Full Text] [Related]
13. SF-6D population norms for the Hong Kong Chinese general population.
Wong CKH; Mulhern B; Cheng GHL; Lam CLK
Qual Life Res; 2018 Sep; 27(9):2349-2359. PubMed ID: 29797176
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
Suthoff E; Kosinski M; Arnaud A; Hodgkins P; Gunduz-Bruce H; Lasser R; Silber C; Sankoh AJ; Li H; Werneburg B; Jonas J; Doherty J; Kanes SJ; Bonthapally V
J Affect Disord; 2022 Jul; 308():19-26. PubMed ID: 35378149
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
[TBL] [Abstract][Full Text] [Related]
16. Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial.
Maspero JF; Khan AH; Philpott C; Hellings PW; Hopkins C; Wagenmann M; Siddiqui S; Msihid J; Nash S; Chuang CC; Kamat S; Rowe PJ; Deniz Y; Jacob-Nara JA
J Asthma Allergy; 2023; 16():323-332. PubMed ID: 37016622
[TBL] [Abstract][Full Text] [Related]
17. EXHANCE-12: 1-year study of the exhalation delivery system with fluticasone (EDS-FLU) in chronic rhinosinusitis.
Palmer JN; Jacobson KW; Messina JC; Kosik-Gonzalez C; Djupesland PG; Mahmoud RA
Int Forum Allergy Rhinol; 2018 Jun; 8(8):869-76. PubMed ID: 29856520
[TBL] [Abstract][Full Text] [Related]
18. Meaningful score changes for SF-36v2, FACIT-fatigue, and RASIQ in rheumatoid arthritis.
Rendas-Baum R; Lin X; Kosinski M; Bjorner JB; Bracher MG; Chen WH
J Patient Rep Outcomes; 2024 Jan; 8(1):9. PubMed ID: 38252223
[TBL] [Abstract][Full Text] [Related]
19. Asenapine treatment and health-related quality of life in patients experiencing bipolar I disorder with mixed episodes: post-hoc analyses of pivotal trials.
Michalak EE; Guiraud-Diawara A; Sapin C
Curr Med Res Opin; 2014 Apr; 30(4):711-8. PubMed ID: 24329543
[TBL] [Abstract][Full Text] [Related]
20. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
